Results 81 to 90 of about 126,024 (329)

HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters

International Journal of Genomics, 2022
Hepatocellular carcinoma (HCC) represents a common malignancy, and mechanisms of acquired sorafenib resistance during the treatment of HCC patients remain elusive.
Xian Zhu, Yinfang Zhang, Yafei Wu, Wenjing Diao, Guilong Deng, Qin Li, Chuanxing Wu   +6 more
doaj   +1 more source

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma

Frontiers in Oncology, 2021
BackgroundSorafenib is the first molecular-targeted drug for the treatment of advanced hepatocellular carcinoma (HCC). However, its treatment efficiency decreases after a short period of time because of the development of drug resistance.
Yi Shi, Yi Shi, Xiaojiang Wang, Xiaojiang Wang, Qiong Zhu, Gang Chen, Gang Chen   +6 more
doaj   +1 more source

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

Theranostics, 2021
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the leading causes of cancer-related death worldwide. Advanced HCC displays strong resistance to chemotherapy, and traditional chemotherapy drugs do not achieve ...
Fanhua Kong, Qi-fa Ye, X. Miao, Xi Liu, Siqi Huang, Li Xiong, Y. Wen, Zijian Zhang   +7 more
semanticscholar   +1 more source

Automating Vascular Biology: An End‐to‐End Automated Workflow for High‐Throughput Blood Vessel‐on‐a‐Chip Production and Multi‐Site Validation

Advanced Healthcare Materials, EarlyView.
AngioPlate384 is a 384‐well open‐top platform that automates production of more than 100 miniaturized, perfusable blood vessels embedded in hydrogel and supported by stromal cells. Stromal‐endothelial co‐culture strengthens blood vessel barrier function and yields responses useful for translational planning. Scalable and automation‐ready, it suits drug
Dawn S. Y. Lin, Hanieh Mohammad Hashemi, Kimia Asadi Jozani, Anushree Chakravarty, Sonya Kouthouridis, Jessica Bonanno, Nicky Anvari, Shravanthi Rajasekar, Feng Zhang, Richard Y. Cheng, Narendra Kumar Singh, Luis Miguel Medina, Marc Durante, Yufang He, Boyang Zhang   +14 more
wiley   +1 more source

Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus

Translational Oncology, 2018
Hepatitis B virus (HBV) targets the liver and is a major driver for liver cancer. Clinical data suggest that HBV infection is associated with reduced response to treatment with the multi-kinase inhibitor sorafenib, the first available molecularly ...
Dvora Witt-Kehati, Alexandra Fridkin, Maya Bitton Alaluf, Romy Zemel, Amir Shlomai   +4 more
doaj   +1 more source

Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC

Molecular Cancer
Sorafenib is a major nonsurgical option for patients with advanced hepatocellular carcinoma (HCC); however, its clinical efficacy is largely undermined by the acquisition of resistance. The aim of this study was to identify the key lncRNA involved in the
Y. Chan, Junyu Wu, Yuanjun Lu, Qiucheng Li, Z. Feng, Lin Xu, Hongchao Yuan, Tingyuan Xing, Cheng Zhang, H. Tan, Yibin Feng, Ning Wang   +11 more
semanticscholar   +1 more source

Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines

Cell Death and Disease, 2021
Sorafenib, a protein kinase inhibitor approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma, has been repeatedly reported to induce ferroptosis by possibly involving inhibition of the cystine/glutamate antiporter, known
Jiashuo Zheng, Mami Sato, Eikan Mishima, Hideyo Sato, B. Proneth, M. Conrad   +5 more
semanticscholar   +1 more source

Evaluation of the Dual Impact of Nanotechnologies on Health and Environment Through Alternative Bridging Models

Advanced Healthcare Materials, EarlyView.
This review explores how alternative invertebrate and small‐vertebrate models advance the evaluation of nanomaterials across medicine and environmental science. By bridging cellular and organismal levels, these models enable integrated assessment of toxicity, biodistribution, and therapeutic performance.
Marie Celine Lefevre, Margherita Bernardeschi, Matteo Battaglini, Gianni Ciofani   +3 more
wiley   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

Synthesis of Sorafenib−Ruthenium Complexes, Investigation of Biological Activities and Applications in Drug Delivery Systems as an Anticancer Agent

Journal of Medicinal Chemistry
Sorafenib, a multiple kinase inhibitor, is widely used as a first-line treatment for hepatocellular carcinoma. However, there is a need for more effective alternatives when sorafenib proves insufficient. In this study, we aimed to design a structure that
Belma Zengin Kurt, Dilek Öztürk Civelek, Elmas Begum Cakmak, Y. Kolcuoğlu, Halil Şenol, Begüm Nurpelin Sağlık Özkan, Aydan Dağ, Kadriye Benkli   +7 more
semanticscholar   +1 more source